New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:59 EDTVCYTVeracyte shares well positioned in 2014, says Leerink
Leerink believes Veracyte shares are well positioned in 2014 with potential catalysts from additional positive coverage decisions and the launch of the Afirma malignant test. The firm raised its price target for shares to $21 from $17 and maintains an Outperform rating on the name.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
07:40 EDTVCYTVeracyte launches Percepta lung cancer diagnosis test
Subscribe for More Information
April 14, 2015
07:35 EDTVCYTVeracyte and General Electric join to develop genomic diagnosis solutions
Veracyte (VCYT) and GE (GE) announced a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms were not disclosed. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.
April 6, 2015
10:02 EDTVCYTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:30 EDTVCYTVeracyte initiated with a Buy at BTIG
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use